| Literature DB >> 31991655 |
Alessandra Stacchiotti1,2, Gaia Favero1, Luigi Fabrizio Rodella1,2.
Abstract
Skeletal muscle disorders are dramatically increasing with human aging with enormous sanitary costs and impact on the quality of life. Preventive and therapeutic tools to limit onset and progression of muscle frailty include nutrition and physical training. Melatonin, the indole produced at nighttime in pineal and extra-pineal sites in mammalians, has recognized anti-aging, anti-inflammatory, and anti-oxidant properties. Mitochondria are the favorite target of melatonin, which maintains them efficiently, scavenging free radicals and reducing oxidative damage. Here, we discuss the most recent evidence of dietary melatonin efficacy in age-related skeletal muscle disorders in cellular, preclinical, and clinical studies. Furthermore, we analyze the emerging impact of melatonin on physical activity. Finally, we consider the newest evidence of the gut-muscle axis and the influence of exercise and probably melatonin on the microbiota. In our opinion, this review reinforces the relevance of melatonin as a safe nutraceutical that limits skeletal muscle frailty and prolongs physical performance.Entities:
Keywords: aging; fibromyalgia; melatonin; mitochondria; mitophagy; physical training; rodents; sarcopenia
Year: 2020 PMID: 31991655 PMCID: PMC7072499 DOI: 10.3390/cells9020288
Source DB: PubMed Journal: Cells ISSN: 2073-4409 Impact factor: 6.600
Main features of healthy and age-related skeletal muscle disorders in mammals.
| Healthy | Age-Related | References | |
|---|---|---|---|
| Myotubes size | Regular | Reduced | [ |
| Satellite cells | Present | Reduced/Absent | [ |
| Mitophagy | Normal | Aberrant | [ |
| Neuromuscular junction | Regular | Absent | [ |
| Triads/Calcium flux | Regular/Present | Disrupted/Absent | [ |
| Mitochondria size/number | Regular | Megamitochondria | [ |
| Inflammation | Absent | Present | [ |
| ROS formation | Absent/Minimal | High | [ |
| ATP production | High | Limited | [ |
| Microcirculation | Effective | Disrupted | [ |
*ROS, reactive oxygen species.
Figure 1Scheme illustrating improvement (+/ in green) and block (−/ in red) of mitochondrial or muscular events induced by dietary melatonin in aged or damaged skeletal muscle.
Melatonin regime in skeletal muscle and exercise in rodents and humans.
| Subjects/Cells | Dose | Times of Administration | Reference-Muscle Type or Exercise |
|---|---|---|---|
| Wistar albino rats | 6 mg/kg s.c. | 5 weeks | [ |
| SAMP8 mice | 10 mg/kg oral | 10 months | [ |
| C57BL/6J mice | 10 mg/kg oral | 2 months | [ |
| NLRP3 KO mice | 10 mg/kg oral | 2 months | [ |
| Pinealectomized Wistar rats | 0.5 mg/kg oral | 45 days | [ |
| L6 cells | 10 nM | 24 h | [ |
| C2C12 | 1–10 nM | 20 min | [ |
| C2C12 cells | 100 mM | 12–24 h | [ |
| C2C12 cells | 100 nM | 16 h | [ |
| Primary muscle cells | 1–100 µM | 24 h | [ |
| Elderly patients | 1 mg/day oral | 4 weeks | [ |
| Sprague-Dawley rats | 10 mg/kg i.p. | 30 min prior and immediately after reperfusion | [ |
| Sprague-Dawley rats | 10 mg/kg i.v. | 10 min prior and 10 min after reperfusion | [ |
| Wistar rats | 10 mg/kg i.p. | 4–14 days | [ |
| Wistar rats | 10 mg/kg i.p. | 1–14 days | [ |
| Wistar rats | 20 mg/kg i.p. | 7 days | [ |
| Sprague-Dawley rats | 2.5 mg/kg 5 mg/kg oral | 1–2 months | [ |
| Sprague-Dawley rats | 5 mg/kg oral | 2 months | [ |
| Wistar rats | 1 mg/kg oral | 16 weeks | [ |
| Adult men | 15 mg oral | Before starting exercise | [ |
| Wistar rats | 20 mg/kg i.p. | Immediately after or 2 h after exercise | [ |
| Adult subjects | 6 mg oral | Before starting exercise | [ |
| Football players | 5 mg oral | 30 days | [ |
| Professionalsoccer players | 6 mg oral | 6 days | [ |
| Adult athletes | 100 mg oral | 4 weeks | [ |
| Adult athletes | 20 mg oral | 2 weeks | [ |
| Wistar rat | 10 mg/kg i.p. | 2 days after exercise | [ |
| Teenage athletes | 10 mg oral | After exercise | [ |
| Adult subjects | 2.5 mg oral | Before exercise | [ |
Figure 2Scheme representation of proposal pathways regulated by melatonin in skeletal muscle. Notably, melatonin mechanisms of action involved mitochondria signaling. CAT: catalase; IL-6: interleukin-6; IGF1: insulin-like growth factor-1; LC3I/LC3II: microtubule-associated protein 1A/1B-light chain 3 free in the cytosol or conjugated to phosphotidylethanolamine during autophagy; NMJ: neuromuscular junction; NRF1 and NRF2: nuclear respiratory factor 1 and 2; PGC-1α: peroxisome proliferative activated receptor gamma coactivator-1alpha; ROS: reactive oxygen species; SIRT1: sirtuin1; SOD: superoxide dismutase; TFAM: mitochondrial transcription factor; TNFα: tumor necrosis factor alpha.